Novartis Delayed Reveal Of Bad Data For $2.1 Million Gene Therapy. Now Patients And Pharma Suffer.

Narasimhan’s poor decision making has had negative consequences not just for Novartis but also for the industry and patients. Let’s hope it’s not repeated.

Read the full post on Forbes - Healthcare